ES
MARKETS / NASDAQ / IVVD
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Invivyd, Inc. IVVD

6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$53.4M
▲ 110.5% vs FY2024
EPS · FY25
$-0.30
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-34.0%
Net margin · FY25
-98.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 53.4M
Revenue, FY2025 · full 6-year series below
Revenue Net income
0.020.040.060.1-0.1202020232025
0.020.040.060.1-0.1202020232025

The company lost 98 cents on every revenue dollar this year.

Per share
USD -0.30
Diluted EPS, FY2025
EPS
0.40.81.2-0.30202020232025
0.40.81.2-0.30202020232025

The company pays no cash dividend.

Profitability
-34.0%
Return on equity, FY2025
ROE
0.250.50.751-34.0%202020232025
0.250.50.751-34.0%202020232025
Operating margin-104.0%
Net margin-98.2%
Return on assets-25.8%

Each USD of equity lost 34 cents this year.

Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.28B
Shares outstanding, FY2025
0.010.28202020232025
0.010.28202020232025
Change, 5 years—
Change, 10 years—

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 276.9M
total assets, end of FY2025
Total assetsUSD 276.9M
EquityUSD 241.5M
CashUSD 226.7M
Current ratio7.24×

Equity funds 87% of total assets.

History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.1
0.0
0.0
·
·
·
Operating income $B
−0.1
−0.2
−0.2
−0.2
−0.2
·
EBITDA $B
·
·
−0.2
−0.2
−0.2
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
·
Net income $B
−0.1
−0.2
−0.2
−0.2
−0.2
−0.0
EPS, diluted $
−0.30
−1.43
−1.81
−2.23
−5.32
·
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−34.0
−138.7
−74.5
−52.8
−92.0
·
Shares out B
0.28
0.12
0.11
0.11
0.11
0.01

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
17 of 17
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed